Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Docetaxel in Recurrent/Metastatic HNSCC
NCT00425750Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2005
- Primary completion
- Jun 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in head and neck squamous cell carcinoma (HNSCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Overall Response Rate at 7.55 months. Started Aug 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00425750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425750.